RE:SoleusI don't have any performance info I can access. Their assets under management have not changed much recently so that indicates they have not been on a really hot performance tear this year. According to Bloomberg, Soleus has $650 million in assets, TH is their sixt largest holding and represents 4% of their total portfolio. 98% of their holdings are classified in the healthcare sector. Their top five holdings are:
BCAB
EPIX
LNTH
CCCC
DICE
BCAB represents 10.5% of their total portfolio. So there would still appear to be significant upside in their potential holdings in TH and we need to remember they are already at a higher effective level of TH ownership due to the in the money warrants they control although I would not expect them to convert them anytime soon. Since the warrants don't trade, they don't count for any value in their portfolio as reported to Bloomberg but we know they have quite a considerable value. We can't really calcuate it because we don't know how many shares they got in the offering. But we know TH effectively represents a larger portion of their portfolio than the 4% number stated above as that is based solely on their common share holdings. I would guess TH makes up an adjusted 5-6% of their portfolio when the warrant exposure is included (assuming the warrants were converted).
palinc2000 wrote: Mission"
The Firm seeks to generate superior risk-adjusted returns through idiosyncratic, catalyst-driven investing with a focus on complex and niche opportunities in the Public and Private space.
I find it interesting that they have increased theur hokdings in THTX during the last Quarter,,....Obviously they are not risk adverse but I am trying to see their record in early stage biotechs and see how successful they have been in being ahead of the curve but did not find much .......,,,Anyone???